🔗 Permalink

Inventor profile of:

Hilmar Erhard Ebersbach

City:

Basel

Country:

Switzerland

Published Applications:

Last publication date:

2025-11-20

Top Assignees for applications by Hilmar Erhard Ebersbach

The entities that hold a legal rights for patent applications filed by inventor Ebersbach Hilmar Erhard:

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA 8 PHILADELPHIA, PA United States
NOVARTIS AG 8 Basel, Switzerland

Recent patent applications by Ebersbach Hilmar Erhard

Hilmar Erhard Ebersbach from Basel, CH has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2025-11-20

US20250353916A1

Chemistry; metallurgy

TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR

#2 | 2023-02-16

US20230052970A1

Chemistry; metallurgy

PHOSPHOGLYCERATE KINASE 1 (PGK) PROMOTERS AND METHODS OF USE FOR EXPRESSING CHIMERIC ANTIGEN RECEPTOR

#3 | 2022-03-03

US20220064316A1

Chemistry; metallurgy

Treatment of cancer using humanized anti-BCMA chimeric antigen receptor

#4 | 2021-05-13

US20210139595A1

Chemistry; metallurgy

TREATMENT OF CANCER USING A CD33 CHIMERIC ANTIGEN RECEPTOR

#5 | 2020-07-09

US20200215171A1

Human necessities

TREATMENT OF CANCER USING A CLL-1 CHIMERIC ANTIGEN RECEPTOR

#6 | 2019-05-23

US20190153061A1

Chemistry; metallurgy

Anti-BCMA chimeric antigen receptor

#7 | 2018-05-03

US20180118834A1

Chemistry; metallurgy

Phosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor

#8 | 2018-02-15

US20180044423A1

Chemistry; metallurgy

Treatment of cancer using a CD33 chimeric antigen receptor

#9 | 2016-04-07

US20160096892A1

Chemistry; metallurgy

Treatment of cancer using a CD33 chimeric antigen receptor

#10 | 2016-02-25

US20160051651A1

Human necessities

Treatment of cancer using a CLL-1 chimeric antigen receptor

#11 | 2016-02-18

US20160046724A1

Chemistry; metallurgy

Nucleic acid encoding a humanized anti-BCMA chimeric antigen receptor

InventorID:

1445215 ⎘